Scarica l'app Stockscreener
31.82
0.95%
0.30
Dopo l'orario di chiusura:
31.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$31.52
Aprire:
$31.42
Volume 24 ore:
856.92K
Relative Volume:
1.66
Capitalizzazione di mercato:
$1.86B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
29.75
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+0.47%
1M Prestazione:
+0.38%
6M Prestazione:
-12.00%
1 anno Prestazione:
+19.85%
Intervallo 1D:
$31.37
$32.78
Intervallo di 1 settimana:
$30.83
$32.78
Portata 52W:
$25.55
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
31.82 | 1.86B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360
Deals of the day-Mergers and acquisitions - marketscreener.com
Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa
Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive
Supernus makes depression drug play with $795m Sage buyout - Yahoo Finance
Supernus enters depression drug market with up to $795 million Sage deal - Reuters
Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks
Supernus to buy Sage for up to $795 million - Axios
Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl
Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio - MarketScreener
Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition - GuruFocus
Supernus to Acquire Sage Therapeutics (SAGE) for $8.50 Per Share - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz
Supernus stock in focus as Sage agrees to buy (SAGE:NASDAQ) - Seeking Alpha
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio | SUPN Stock News - GuruFocus
Supernus to acquire Sage Therapeutics for up to $795 million - Investing.com
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire
GAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Cut by Rhumbline Advisers - Defense World
California State Teachers Retirement System Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Two Sigma Advisers LP Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LP - Defense World
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
| Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
1.05%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):